The Allen Institute is launching a $200 million initiative to explore specific neurodegenerative diseases and even develop drugs for those conditions.
A Seattle-based nonprofit known for basic brain research is launching a $200 million initiative to translate its knowledge into drug development for neurodegenerative diseases, including …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Brain mapping effort searches for roots of Parkinson’s and other diseases
AI-Powered drug discovery could transform treatment development for Alzheimer’s, Parkinson’s and other brain disorders.
Deep Science Ventures and Medicines Discovery Catapult partner to tackle brain drug delivery
AI’s next pharma challenge: tackling costly and risky clinical trials
Reid Hoffman says the next AI gold rush is in medicine
ALZHEIMER'S & BRAIN AWARENESS MONTH: TAKE CHARGE OF YOUR BRAIN HEALTH
Allen Institute initiative aims to capture earliest cellular changes and identify new drug targets
Researchers are increasingly using AI to accelerate the search for treatments for neurological conditions such as Alzheimers,…
NeuroXT and BIDMC Expand Collaboration to Advance AI-Driven Precision Treatment in Alzheimer's Disease
Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a…
The Biological Computing Co. (TBC) has raised $25 million in seed funding, Fortune has learned.
Researchers develop a bioluminescent sensor to test protein activation, speeding up a lengthy step in drug discovery for…
